Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981201 · ClinicalTrials.gov registry record · Phase 3
Celecoxib as a Chemopreventive Agent in Current and Former Smokers
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT00981201: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00981201 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 219 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00981201, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is: * To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers. * To examine the toxicity associated with celecoxib administration. * To measure the effect of celecoxib treatment on arachidonic acid metabolites in the bronchial epithelium of current and former smokers.
Interventions
- DRUG Placebo
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00981201
The ClinicalTrials.gov registry entry for NCT00981201 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00981201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00981201 about?
NCT00981201 is a clinical study titled "Celecoxib as a Chemopreventive Agent in Current and Former Smokers". The purpose of this study is: * To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers. * To examine the toxicity associated with celecoxib administration. * To measure the effect of celecoxib treat...
What is the current status of trial NCT00981201?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2001-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00981201?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00981201?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.